莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300006 莱美药业

交易中 07-17 11:17:24

{"stockData":{"symbol":"300006","market":"SZ","secType":"STK","nameCN":"莱美药业","latestPrice":2.32,"timestamp":1721186244000,"preClose":2.33,"halted":0,"volume":2716700,"delay":0,"floatShares":1056000000,"shares":1056000000,"eps":-0.0094,"marketStatus":"交易中","marketStatusCode":2,"change":-0.01,"latestTime":"07-17 11:17:24","open":2.34,"high":2.35,"low":2.31,"amount":6320300,"amplitude":0.0172,"askPrice":2.33,"askSize":351,"bidPrice":2.32,"bidSize":552,"shortable":0,"etf":0,"ttmEps":-0.0094,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1721187000000},"adr":0,"adjPreClose":2.33,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":2.56,"lowLimit":2.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1055911205,"pbRate":1.19,"roa":"--","roe":"--","epsLYR":-0.0085,"committee":0.011308,"marketValue":2450000000,"floatMarketCap":2450000000,"peRate":-246.808514,"changeRate":-0.0043,"turnoverRate":0.0026,"status":1},"requestUrl":"/m/hq/s/300006","defaultTab":"news","newsList":[{"id":"2450336519","title":"莱美药业：公司前十大股东无出借股份情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2450336519","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450336519?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:03","pubTimestamp":1720688612,"startTime":"0","endTime":"0","summary":"证券之星消息，莱美药业07月11日在投资者关系平台上答复投资者关心的问题。公司前十大股东无出借股份情况。公司将严格按照深交所规定履行信息披露义务，请关注公司相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100033478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300006","BK0070"],"gpt_icon":0},{"id":"2449797523","title":"莱美药业（300006）7月5日主力资金净买入544.94万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449797523","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449797523?lang=zh_cn&edition=full","pubTime":"2024-07-08 09:11","pubTimestamp":1720401114,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月5日收盘，莱美药业报收于2.44元，上涨6.09%，换手率1.5%，成交量15.8万手，成交额3774.24万元。近5日资金流向一览见下表：莱美药业融资融券信息显示，融资方面，当日融资买入336.9万元，融资偿还199.06万元，融资净买入137.84万元。融券方面，融券卖出3.4万股，融券偿还9300.0股，融券余量14.81万股，融券余额36.14万元。莱美药业主营业务：医药制造。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800001866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2441228801","title":"莱美药业(300006.SZ)：邱宇和中恒集团签署《表决权委托协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2441228801","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441228801?lang=zh_cn&edition=full","pubTime":"2024-06-05 17:06","pubTimestamp":1717578401,"startTime":"0","endTime":"0","summary":"格隆汇6月5日丨莱美药业(300006.SZ)公布，股东邱宇先生于2023年4月7日与控股股东广西梧州中恒集团股份有限公司（简称“中恒集团”）签署了《之补充协议》，该协议将于2024年6月7日到期。2024年6月4日，邱宇先生和中恒集团签署了《表决权委托协议》，本次表决权委托期限至2026年6月7日。本次协议的签署不会导致上市公司控制权发生变更，亦未触发《上市公司收购管理办法》规定的要约收购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406051707589590a38d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406051707589590a38d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0015","BK0028","BK0012","BK0070","BK0188","BK0239","300006","600252","BK0077"],"gpt_icon":0},{"id":"2440400891","title":"中恒集团(600252.SH)子公司莱美药业收到盐酸纳洛酮注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440400891","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440400891?lang=zh_cn&edition=full","pubTime":"2024-06-04 17:54","pubTimestamp":1717494889,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中恒集团(600252.SH)发布公告，公司控股子公司重庆莱美药业股份有限公司(简称“莱美药业”)收到国家药品监督管理局核准签发的规格为1ml:0.4mg的盐酸纳洛酮注射液《药品注册证书》，盐酸纳洛酮注射液为阿片类受体拮抗药，用于阿片类药物复合麻醉术后，拮抗该类药物所致的呼吸抑制，促使病人苏醒;用于阿片类药物过量，完全或部分逆转阿片类药物引起的呼吸抑制;用于解救急性乙醇中毒;用于急性阿片类药物过量的诊断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","300006","BK0028","BK0188","BK0012","BK0015","BK0239","BK0077","600252"],"gpt_icon":0},{"id":"2440401049","title":"莱美药业(300006.SZ)：盐酸纳洛酮注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440401049","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440401049?lang=zh_cn&edition=full","pubTime":"2024-06-04 17:04","pubTimestamp":1717491882,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的规格为1ml:0.4mg的盐酸纳洛酮注射液《药品注册证书》。据悉，盐酸纳洛酮注射液由美国ADAPT制药公司研发，目前在美国和日本均有上市，尚未进口国内。盐酸纳洛酮注射液为阿片类受体拮抗药，用于阿片类药物复合麻醉术后，拮抗该类药物所致的呼吸抑制，促使病人苏醒;用于阿片类药物过量，完全或部分逆转阿片类药物引起的呼吸抑制;用于解救急性乙醇中毒;用于急性阿片类药物过量的诊断。本次公司取得盐酸纳洛酮注射液(1ml:0.4mg)《药品注册证书》，有利于进一步丰富公司产品线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300006","BK0239","BK0070"],"gpt_icon":0},{"id":"2430492824","title":"莱美药业（300006）2024年一季报简析：净利润减25.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430492824","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430492824?lang=zh_cn&edition=full","pubTime":"2024-04-25 06:12","pubTimestamp":1713996744,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期莱美药业发布2024年一季报。根据财报显示，本报告期中莱美药业净利润减25.9%。截至本报告期末，公司营业总收入1.81亿元，同比下降20.09%，归母净利润-457.53万元，同比下降25.9%。其中，毛利率64.82%，同比减8.43%，净利率0.02%，同比增100.52%，销售费用、管理费用、财务费用总计1.13亿元，三费占营收比62.26%，同比减6.82%，每股净资产1.97元，同比减2.21%，每股经营性现金流0.07元，同比增725.99%，每股收益-0.0元，同比减26.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500011900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006"],"gpt_icon":0},{"id":"2429161464","title":"莱美药业最新公告：一季度净亏损457.53万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429161464","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429161464?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:01","pubTimestamp":1713866476,"startTime":"0","endTime":"0","summary":"莱美药业公布2024年一季度报告，报告期营业收入1.81亿元，同比下降20.09%；归属于上市公司股东的净利润亏损457.53万元。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300035359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"gpt_icon":0},{"id":"2429166919","title":"莱美药业(300006.SZ)发布一季度业绩，净亏损457.53万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429166919","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429166919?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:24","pubTimestamp":1713864252,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布2024年第一季度报告，该公司营业收入为1.81亿元，同比减少20.09%。归属于上市公司股东的净亏损为457.53万元，同比扩大。归属于上市公司股东的扣除非经常性损益的净亏损为743.37万元，同比收窄。基本每股亏损为0.0043元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300006","BK0070","BK0239"],"gpt_icon":0},{"id":"2422758327","title":"莱美药业减亏术","url":"https://stock-news.laohu8.com/highlight/detail?id=2422758327","media":"媒体滚动","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2422758327?lang=zh_cn&edition=full","pubTime":"2024-03-24 23:35","pubTimestamp":1711294500,"startTime":"0","endTime":"0","summary":"　　莱美药业于3月23日披露2023年年报，公司2023年净利亏损892.73万元，同比大幅减亏。　　2023年前三季度归属净利润亏损逾5400万元的莱美药业，2023年全年亏损出现收窄，仅亏损892.73万元。　　莱美药业2023年年报显示，报告期内，公司实现营业收入约为8.96亿元，同比增长1.24%；对应实现的归属净利润约为-892.73万元，上年同期净利为-6870.52万元，同比大幅减亏；对应实现的扣非后净利润约为-5993.33万元，上年同期为-1.15亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-03-24/doc-inapmyzm0590923.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-03-24/doc-inapmyzm0590923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300006","BK0070","BK0239"],"gpt_icon":0},{"id":"2420257215","title":"莱美药业(300006.SZ)：奥美拉唑镁肠溶片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2420257215","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420257215?lang=zh_cn&edition=full","pubTime":"2024-03-19 15:43","pubTimestamp":1710834180,"startTime":"0","endTime":"0","summary":"莱美药业公告，公司收到国家药品监督管理局核准签发的规格为20mg的奥美拉唑镁肠溶片《药品注册证书》。股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-19/doc-inanvynt7089208.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-19/doc-inanvynt7089208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2420056465","title":"本周A股328.58亿元限售股解禁，广州港、莱美药业、返利科技、宿迁联盛、长龄液压等解禁压力较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2420056465","media":"金融界网站","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2420056465?lang=zh_cn&edition=full","pubTime":"2024-03-18 07:55","pubTimestamp":1710719700,"startTime":"0","endTime":"0","summary":"未来四周解禁情况本周解禁数量最多的是广州港，广州港3月15日公告称，公司限售股份约10.14亿股将于2024年3月21日解禁并上市流通，占公司总股本比例为13.43%。解禁股东明细如下：其他解禁数量较大的公司有莱美药业、返利科技、宿迁联盛、同力日升、宏源药业、长龄液压等。解禁股东明细如下：从实际解禁市值规模来看，广州港位居首位，中无人机次之，同力日升在第三。解禁量占总股本比例方面，19股解禁比例超10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-03-18/doc-inansyiw5742890.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-03-18/doc-inansyiw5742890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603065","BK0270","159982","601228","605389","BK0071","BK0259","300006","BK0239","BK0217","BK0229","BK0000","BK0102","BK0173","399300","BK0070","600228","BK0007"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"重庆市南岸区玉马路99号","stockEarnings":[{"period":"1week","weight":0.0043},{"period":"1month","weight":-0.0528},{"period":"3month","weight":-0.1402},{"period":"6month","weight":-0.3285},{"period":"1year","weight":-0.3147},{"period":"ytd","weight":-0.3737}],"companyName":"重庆莱美药业股份有限公司","boardCode":"AI0027","perCapita":"33634股","boardName":"医药制造业","registeredCapital":"105591万元","compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.031},{"period":"6month","weight":0.0459},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.0005}],"survey":"　　重庆莱美药业股份有限公司的主要业务为医药制造，公司产品品种丰富，结构合理，公司主要产品为化药，涵盖特色专科类（主要包括抗肿瘤药、消化系统药、肠外营养药）、抗感染类等。公司重点品种纳米炭混悬注射液(卡纳琳)，系首款获得CFDA批准的淋巴示踪剂，卡纳琳连续四年获得“中国化学制药行业原研药,专利药优秀产品品牌”,连续两年获得“中国化学制药行业其他各科用药优秀产品品牌”,获得“制造业单项冠军产品(2019-2021年)”,“2021年中国产学研合作创新与促进奖”等多项荣誉称号。","serverTime":1721186249243,"listedPrice":16.5,"stockholders":"31391人(较上一季度减少1.78%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱美药业,300006,莱美药业股票,莱美药业股票老虎,莱美药业股票老虎国际,莱美药业行情,莱美药业股票行情,莱美药业股价,莱美药业股市,莱美药业股票价格,莱美药业股票交易,莱美药业股票购买,莱美药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}